The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Carlsten, Mattias [verfasserIn] Jädersten, Martin [verfasserIn] Hellström, Anna [verfasserIn] Littmann, Karin [verfasserIn] Melén, Christopher M. [verfasserIn] Junlén, Henna Riikka [verfasserIn] Sonnevi, Kristina [verfasserIn] Ljungman, Per [verfasserIn] Björkstrand, Bo [verfasserIn] Wahlin, Björn Engelbrekt [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Experimental hematology & oncology - London : Biomed Central, 2012, 8(2019), 1 vom: 18. März |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2019 ; number:1 ; day:18 ; month:03 |
| Links: |
|---|
| DOI / URN: |
10.1186/s40164-019-0131-3 |
|---|
| Katalog-ID: |
SPR033189927 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033189927 | ||
| 003 | DE-627 | ||
| 005 | 20230519121030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40164-019-0131-3 |2 doi | |
| 035 | |a (DE-627)SPR033189927 | ||
| 035 | |a (SPR)s40164-019-0131-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Carlsten, Mattias |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. | ||
| 650 | 4 | |a Autologous stem cell transplantation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ASCT |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a BEAM |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lymphoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Real-world |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Survival |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Jädersten, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hellström, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Littmann, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Melén, Christopher M. |e verfasserin |4 aut | |
| 700 | 1 | |a Junlén, Henna Riikka |e verfasserin |4 aut | |
| 700 | 1 | |a Sonnevi, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ljungman, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Björkstrand, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Wahlin, Björn Engelbrekt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental hematology & oncology |d London : Biomed Central, 2012 |g 8(2019), 1 vom: 18. März |w (DE-627)718833341 |w (DE-600)2669066-4 |x 2162-3619 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:1 |g day:18 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40164-019-0131-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 1 |b 18 |c 03 | ||
| author_variant |
m c mc m j mj a h ah k l kl c m m cm cmm h r j hr hrj k s ks p l pl b b bb b e w be bew |
|---|---|
| matchkey_str |
article:21623619:2019----::hkrlnkeprecoatlgusecltaslnainolmhmaouainae |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1186/s40164-019-0131-3 doi (DE-627)SPR033189927 (SPR)s40164-019-0131-3-e DE-627 ger DE-627 rakwb eng 610 ASE Carlsten, Mattias verfasserin aut The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. Autologous stem cell transplantation (dpeaa)DE-He213 ASCT (dpeaa)DE-He213 BEAM (dpeaa)DE-He213 Lymphoma (dpeaa)DE-He213 Real-world (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Jädersten, Martin verfasserin aut Hellström, Anna verfasserin aut Littmann, Karin verfasserin aut Melén, Christopher M. verfasserin aut Junlén, Henna Riikka verfasserin aut Sonnevi, Kristina verfasserin aut Ljungman, Per verfasserin aut Björkstrand, Bo verfasserin aut Wahlin, Björn Engelbrekt verfasserin aut Enthalten in Experimental hematology & oncology London : Biomed Central, 2012 8(2019), 1 vom: 18. März (DE-627)718833341 (DE-600)2669066-4 2162-3619 nnns volume:8 year:2019 number:1 day:18 month:03 https://dx.doi.org/10.1186/s40164-019-0131-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 1 18 03 |
| spelling |
10.1186/s40164-019-0131-3 doi (DE-627)SPR033189927 (SPR)s40164-019-0131-3-e DE-627 ger DE-627 rakwb eng 610 ASE Carlsten, Mattias verfasserin aut The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. Autologous stem cell transplantation (dpeaa)DE-He213 ASCT (dpeaa)DE-He213 BEAM (dpeaa)DE-He213 Lymphoma (dpeaa)DE-He213 Real-world (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Jädersten, Martin verfasserin aut Hellström, Anna verfasserin aut Littmann, Karin verfasserin aut Melén, Christopher M. verfasserin aut Junlén, Henna Riikka verfasserin aut Sonnevi, Kristina verfasserin aut Ljungman, Per verfasserin aut Björkstrand, Bo verfasserin aut Wahlin, Björn Engelbrekt verfasserin aut Enthalten in Experimental hematology & oncology London : Biomed Central, 2012 8(2019), 1 vom: 18. März (DE-627)718833341 (DE-600)2669066-4 2162-3619 nnns volume:8 year:2019 number:1 day:18 month:03 https://dx.doi.org/10.1186/s40164-019-0131-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 1 18 03 |
| allfields_unstemmed |
10.1186/s40164-019-0131-3 doi (DE-627)SPR033189927 (SPR)s40164-019-0131-3-e DE-627 ger DE-627 rakwb eng 610 ASE Carlsten, Mattias verfasserin aut The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. Autologous stem cell transplantation (dpeaa)DE-He213 ASCT (dpeaa)DE-He213 BEAM (dpeaa)DE-He213 Lymphoma (dpeaa)DE-He213 Real-world (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Jädersten, Martin verfasserin aut Hellström, Anna verfasserin aut Littmann, Karin verfasserin aut Melén, Christopher M. verfasserin aut Junlén, Henna Riikka verfasserin aut Sonnevi, Kristina verfasserin aut Ljungman, Per verfasserin aut Björkstrand, Bo verfasserin aut Wahlin, Björn Engelbrekt verfasserin aut Enthalten in Experimental hematology & oncology London : Biomed Central, 2012 8(2019), 1 vom: 18. März (DE-627)718833341 (DE-600)2669066-4 2162-3619 nnns volume:8 year:2019 number:1 day:18 month:03 https://dx.doi.org/10.1186/s40164-019-0131-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 1 18 03 |
| allfieldsGer |
10.1186/s40164-019-0131-3 doi (DE-627)SPR033189927 (SPR)s40164-019-0131-3-e DE-627 ger DE-627 rakwb eng 610 ASE Carlsten, Mattias verfasserin aut The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. Autologous stem cell transplantation (dpeaa)DE-He213 ASCT (dpeaa)DE-He213 BEAM (dpeaa)DE-He213 Lymphoma (dpeaa)DE-He213 Real-world (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Jädersten, Martin verfasserin aut Hellström, Anna verfasserin aut Littmann, Karin verfasserin aut Melén, Christopher M. verfasserin aut Junlén, Henna Riikka verfasserin aut Sonnevi, Kristina verfasserin aut Ljungman, Per verfasserin aut Björkstrand, Bo verfasserin aut Wahlin, Björn Engelbrekt verfasserin aut Enthalten in Experimental hematology & oncology London : Biomed Central, 2012 8(2019), 1 vom: 18. März (DE-627)718833341 (DE-600)2669066-4 2162-3619 nnns volume:8 year:2019 number:1 day:18 month:03 https://dx.doi.org/10.1186/s40164-019-0131-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 1 18 03 |
| allfieldsSound |
10.1186/s40164-019-0131-3 doi (DE-627)SPR033189927 (SPR)s40164-019-0131-3-e DE-627 ger DE-627 rakwb eng 610 ASE Carlsten, Mattias verfasserin aut The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. Autologous stem cell transplantation (dpeaa)DE-He213 ASCT (dpeaa)DE-He213 BEAM (dpeaa)DE-He213 Lymphoma (dpeaa)DE-He213 Real-world (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Jädersten, Martin verfasserin aut Hellström, Anna verfasserin aut Littmann, Karin verfasserin aut Melén, Christopher M. verfasserin aut Junlén, Henna Riikka verfasserin aut Sonnevi, Kristina verfasserin aut Ljungman, Per verfasserin aut Björkstrand, Bo verfasserin aut Wahlin, Björn Engelbrekt verfasserin aut Enthalten in Experimental hematology & oncology London : Biomed Central, 2012 8(2019), 1 vom: 18. März (DE-627)718833341 (DE-600)2669066-4 2162-3619 nnns volume:8 year:2019 number:1 day:18 month:03 https://dx.doi.org/10.1186/s40164-019-0131-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 1 18 03 |
| language |
English |
| source |
Enthalten in Experimental hematology & oncology 8(2019), 1 vom: 18. März volume:8 year:2019 number:1 day:18 month:03 |
| sourceStr |
Enthalten in Experimental hematology & oncology 8(2019), 1 vom: 18. März volume:8 year:2019 number:1 day:18 month:03 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Autologous stem cell transplantation ASCT BEAM Lymphoma Real-world Survival |
| dewey-raw |
610 |
| isfreeaccess_bool |
true |
| container_title |
Experimental hematology & oncology |
| authorswithroles_txt_mv |
Carlsten, Mattias @@aut@@ Jädersten, Martin @@aut@@ Hellström, Anna @@aut@@ Littmann, Karin @@aut@@ Melén, Christopher M. @@aut@@ Junlén, Henna Riikka @@aut@@ Sonnevi, Kristina @@aut@@ Ljungman, Per @@aut@@ Björkstrand, Bo @@aut@@ Wahlin, Björn Engelbrekt @@aut@@ |
| publishDateDaySort_date |
2019-03-18T00:00:00Z |
| hierarchy_top_id |
718833341 |
| dewey-sort |
3610 |
| id |
SPR033189927 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033189927</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519121030.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s40164-019-0131-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033189927</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40164-019-0131-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carlsten, Mattias</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autologous stem cell transplantation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ASCT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">BEAM</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Real-world</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jädersten, Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hellström, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Littmann, Karin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melén, Christopher M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Junlén, Henna Riikka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sonnevi, Kristina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ljungman, Per</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Björkstrand, Bo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wahlin, Björn Engelbrekt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Experimental hematology & oncology</subfield><subfield code="d">London : Biomed Central, 2012</subfield><subfield code="g">8(2019), 1 vom: 18. März</subfield><subfield code="w">(DE-627)718833341</subfield><subfield code="w">(DE-600)2669066-4</subfield><subfield code="x">2162-3619</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:03</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s40164-019-0131-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">03</subfield></datafield></record></collection>
|
| author |
Carlsten, Mattias |
| spellingShingle |
Carlsten, Mattias ddc 610 misc Autologous stem cell transplantation misc ASCT misc BEAM misc Lymphoma misc Real-world misc Survival The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| authorStr |
Carlsten, Mattias |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)718833341 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2162-3619 |
| topic_title |
610 ASE The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 Autologous stem cell transplantation (dpeaa)DE-He213 ASCT (dpeaa)DE-He213 BEAM (dpeaa)DE-He213 Lymphoma (dpeaa)DE-He213 Real-world (dpeaa)DE-He213 Survival (dpeaa)DE-He213 |
| topic |
ddc 610 misc Autologous stem cell transplantation misc ASCT misc BEAM misc Lymphoma misc Real-world misc Survival |
| topic_unstemmed |
ddc 610 misc Autologous stem cell transplantation misc ASCT misc BEAM misc Lymphoma misc Real-world misc Survival |
| topic_browse |
ddc 610 misc Autologous stem cell transplantation misc ASCT misc BEAM misc Lymphoma misc Real-world misc Survival |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Experimental hematology & oncology |
| hierarchy_parent_id |
718833341 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Experimental hematology & oncology |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)718833341 (DE-600)2669066-4 |
| title |
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| ctrlnum |
(DE-627)SPR033189927 (SPR)s40164-019-0131-3-e |
| title_full |
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| author_sort |
Carlsten, Mattias |
| journal |
Experimental hematology & oncology |
| journalStr |
Experimental hematology & oncology |
| lang_code |
eng |
| isOA_bool |
true |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| author_browse |
Carlsten, Mattias Jädersten, Martin Hellström, Anna Littmann, Karin Melén, Christopher M. Junlén, Henna Riikka Sonnevi, Kristina Ljungman, Per Björkstrand, Bo Wahlin, Björn Engelbrekt |
| container_volume |
8 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Carlsten, Mattias |
| doi_str_mv |
10.1186/s40164-019-0131-3 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| title_auth |
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| abstract |
Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. |
| abstractGer |
Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. |
| abstract_unstemmed |
Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 |
| url |
https://dx.doi.org/10.1186/s40164-019-0131-3 |
| remote_bool |
true |
| author2 |
Jädersten, Martin Hellström, Anna Littmann, Karin Melén, Christopher M. Junlén, Henna Riikka Sonnevi, Kristina Ljungman, Per Björkstrand, Bo Wahlin, Björn Engelbrekt |
| author2Str |
Jädersten, Martin Hellström, Anna Littmann, Karin Melén, Christopher M. Junlén, Henna Riikka Sonnevi, Kristina Ljungman, Per Björkstrand, Bo Wahlin, Björn Engelbrekt |
| ppnlink |
718833341 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s40164-019-0131-3 |
| up_date |
2024-07-03T17:09:29.587Z |
| _version_ |
1803578580239646720 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033189927</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519121030.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s40164-019-0131-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033189927</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40164-019-0131-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carlsten, Mattias</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including $ CD34^{+} $ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia. Results The 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million $ CD34^{+} $ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests. Conclusions Before starting conditioning, patients should have preferably harvested ≥ 5 million $ CD34^{+} $ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autologous stem cell transplantation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ASCT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">BEAM</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Real-world</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jädersten, Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hellström, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Littmann, Karin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melén, Christopher M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Junlén, Henna Riikka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sonnevi, Kristina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ljungman, Per</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Björkstrand, Bo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wahlin, Björn Engelbrekt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Experimental hematology & oncology</subfield><subfield code="d">London : Biomed Central, 2012</subfield><subfield code="g">8(2019), 1 vom: 18. März</subfield><subfield code="w">(DE-627)718833341</subfield><subfield code="w">(DE-600)2669066-4</subfield><subfield code="x">2162-3619</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:03</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s40164-019-0131-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">03</subfield></datafield></record></collection>
|
| score |
7.400529 |